INTRODUCTION

Acute myocardial infarction (AMI) is a leading cause of deaths; governments and patients have to carry big economic burden in both developed and developing countries from the disease itself and post-infarction heart failure (HF) in this post-drug eluting stenting era. The medicine has been focusing on the timely reperfusion therapy and decreasing infarction size to reduce the mortality and morbidity. From the recent timely and costly efforts, the myocardial injury from delayed revascularization was successful to reduce infarct size. In contrast, previous challenges to reduce the reperfusion injury were disappointing, and there have been no available practical strategies to date. We need, therefore, new strategies in addition to optimal reperfusion therapy to improve clinical outcomes of AMI.

Therapeutic hypothermia (TH) has been used to improve neurologic outcome of outside hospital cardiac arrest survivor. Furthermore, in experimental studies on infarcted model and pilot studies on conscious patients with acute myocardial infarction, therapeutic hypothermia successfully reduced infarct size and microvascular resistance. Therefore, mild therapeutic hypothermia has received an attention as a promising solution for reduction of infarction size after acute myocardial infarction which are not completely solved despite of optimal reperfusion therapy. Nevertheless, the results from randomized clinical trials failed to prove the cardioprotective effects of therapeutic hypothermia or showed beneficial effects only in limited subgroups. In this article, we reviewed rationale for therapeutic hypothermia and possible mechanisms from previous studies, effective methods for clinical application to the patients with acute myocardial infarction, lessons from current clinical trials and future directions.

Key Words: Hypothermia, induced; myocardial infarction; myocardial reperfusion injury
prognosis.

Recent clinical trials failed to prove the infarct size reduction of mild TH in AMI patients.\textsuperscript{22-25} Nonetheless, negative results from clinical trials could not ignore cardioprotective effect of TH which has been consistently proved in experimental studies.

In this review, we focused on the TH for cardioprotection in myocardial infarction and discussed the results of past attempts to reduce ischemia-reperfusion injury by using hypothermia, rationale for TH, possible mechanisms from experimental studies and lessons from current clinical trials and future directions.

**BEST TARGET TEMPERATURE IN THERAPEUTIC HYPOTHERMIA**

Hypothermia, core body temperature <35°C, can be a life-threatening emergency but can be induced therapeutically in special medical conditions.\textsuperscript{26,27} TH is classified according to the target body temperature; 1) mild; 32–35°C, 2) moderate; 28–32°C, 3) severe; 20–28°C, or 4) profound; <20°C.\textsuperscript{27}

Experimental data showed strong correlation with target temperature and infarct size; every 1°C of temperature reduction results in 10–20% decrease of infarct size in swine and ovine.\textsuperscript{27,28} Hence, lower temperature is better in reducing infarct size. However, less than 30°C of hyperthermia frequently develops atrial fibrillation, and spontaneous ventricular fibrillation is induced at <28°C in most mammalian species.\textsuperscript{26,27} Mild hypothermia may induce decreasing heart rate without deviation of stroke volume and mean artery pressure, and is well tolerated in experimental animals and human.\textsuperscript{27} Mild hypothermia of 32–34°C is generally accepted goal of TH.

**RATIONALE FOR MILD HYPOTHERMIA**

**Ischemia-reperfusion injury**

Irreversible myocardial damage after AMI is divided into ischemic and reperfusion injury, but they share some mechanisms and sometimes hard to clearly separate two components.\textsuperscript{29} Of course, longer duration of coronary artery occlusion (CAO) leads to larger infarct size, and therefore, early reperfusion improves prognosis by reducing infarct size and mortality.\textsuperscript{26-32} Current guidelines strongly recommends within 90 minutes coronary angioplasty as timely reperfusion for ST elevation AMI.\textsuperscript{33}

However, timely reperfusion is not enough to solve the reperfusion injury related problems. About 40–50% reduction of infarct size can be achieved by timely reperfusion and half of the remaining infarct size is contributed by reperfusion injury.\textsuperscript{10,34} So, successful prevention of reperfusion injury possibly reduces infarct size additional 25%.

As for the underlying mechanisms about reperfusion injury, myocardial damages resulted from restoring epicardial coro-

nary blood flow, are multifactorial and not fully understood to date.\textsuperscript{29,35-37} TH is one of the promising strategies to prevent reperfusion injury,\textsuperscript{20,38} and we focused TH and its mechanism for cardioprotection in this review.

**Possible mechanism of TH**

Major concept of cooling-induced cardioprotection is energy preservation; 1) reduced metabolic demands of myocardium and preserved adenosine triphosphate and glycogen, 2) enhanced cellular membrane stability from reduced acidosis, 3) reduction of Na\textsuperscript{+} and Ca\textsuperscript{2+} overload,\textsuperscript{17,18,39} and 4) enhanced mitochondrial membrane stability by inhibition of calcium induced mitochondrial permeability transition pore (MPTP) opening; maintained ion homeostasis during ischemia and reperfusion, and preserved microvascular structures.\textsuperscript{19}

The beneficial effect of cooling was observed in mitochondria from non-reperfused as well as reperfused myocardium. Tissier, et al.\textsuperscript{19} reported that in non-reperfused conditions, Ca\textsuperscript{2+} concentration required to open MPTP was slightly decreased in hypothermic hearts (-16%), whereas -49% drop in normothermic hearts. In hearts subjected to ischemia-reperfusion, a significant decrease was observed in both hypothermic (-37%) and control (-68%) hearts, although the decrease was greater in the latter.\textsuperscript{19} Proposed protective signal transduction is via enhancing ERK pathway during ischemia,\textsuperscript{19} while pre/post conditioning-related protection is dependent on activation of ERK in the first minutes of reperfusion.\textsuperscript{27,41}

**TIMING, SPEED, AND DURATION**

Delayed and slow TH up to 8 hours after ROSC showed favorable neurologic outcome and reduced mortality in the patients experienced with outside hospital cardiac arrest.\textsuperscript{16} Contrary, rapid early initiation before revascularization is essential to reduce infarct size in the conscious patients with AMI. Experimental studies consistently showed that rapid and earlier initiation of TH is better for reducing infarct size.\textsuperscript{17,43} Pre-perfusion TH in ischemic model showed about 40% infarct size reductions, although there were some discrepancies between studies.\textsuperscript{12,44} Hence, induction of TH before reperfusion is accepted as an essential element.

Induction of TH during reperfusion failed to reveal statistically significant reduction of infarct size, but limited no-reflow by improving microvascular resistance.\textsuperscript{21,45-47} Microvascular resistance is one of important predictors of clinical outcomes in patients with AMI.\textsuperscript{45-47} To attenuate reperfusion injury and microvascular alteration, maintenance of TH after revascularization is another important issue needed to be addressed.\textsuperscript{15,16,38}
METHODS OF THERAPEUTIC HYPOTHERMIA

Experimental studies have used various methods to induce hypothermia in AMI models; surface cooling, endovascular cooling, cold saline infusion into coronary artery, pericardial perfusion, extracorporeal blood cooling, total liquid ventilation and peritoneal lavage. Although the critical parameters determining benefit would be early cooling initiation and rapid cooling rate, some of those methods are too invasive for clinical use. So-called ultra-fast cooling methods, including extracorporeal blood cooling, total liquid ventilation and pericardial perfusion are too invasive and have a chance to delay reperfusion procedures.

Some of the methods are relatively safe and were applied to the patients with cardiac arrest or myocardial infarction (Table 1). Surface cooling can be used for total body cover or partial body pad. Conventional method had limitation of slow cooling rate, especially in obese patients. Newer surface cooling device with convective-immersion method improved the cooling rate, however, it might be difficult to perform coronary intervention with this device which requires covering entire body. A pilot study introduced a pad type topical surface cooling device which covers trunk of a patient with AMI eligible for primary percutaneous coronary intervention (PCI) and proved its safety but showed slow cooling rate as 79 minutes to target <34.5°C (1.5°C/hr). Hence, technical evolution or combined use with other method may be necessary to achieve rapid cooling.

Transnasal evaporative cooling is to spray a liquid coolant-oxygen mixture into nasal passage and brain. It is a portable device, easy to apply and relatively safe, however, can induce severe epistaxis in patients with coagulopathy. Intravenous infusion of cold saline (4°C) clearly brings about rapid cooling at first one hour with large volume infusion. However, it can result in respiratory problems related to volume overloading and worsened ejection fraction.

Endovascular cooling catheter of heat-exchange with a balloon at the tip is positioned inferior vena cava through a femoral vein. Basic method is heat exchange by long cold balloon without infusion of cool saline to patients. Even though rapid cooling rate of pilot study, registry data failed to present rapid cooling rate (Table 1). Endovascular catheter alone might be insufficient to achieve target temperature before reperfusion for AMI without delaying PCI. Recently published clinical trials, which combined the use of endovascular cooling with intravenous cold saline infusion, showed about 6°C/hr cooling rate.

Automated peritoneal lavage can rapidly achieve target temperature due to large surface area, however, it is an invasive procedure. Peritoneal lavage with large fluid volume may induce respiratory distress due to diaphragm elevation, and has a chance of major organ bleeding with peritoneal puncture and limited candidate due to abdominal pathology or morbid obesity.

RESULTS FROM CLINICAL TRIALS AND POOLED ANALYSIS

Initial two randomized clinical trials (RCTs) were presented at scientific meetings but not yet published, and both trials adopted combination hypothermia of intravenous cold saline infusion and endovascular cooling catheter. The Cooling as an Adjunctive Therapy to Percutaneous Intervention in patients with AMI (COOL-MI trial, n=392) showed no significant reduction of infarct size at 30 days, evidenced by heart single-photon emission computed tomography (control vs. hypothermia: 14.1% vs. 13.8%, p=0.86) but anterior AMI (18.2% vs. 9.3%, p=0.05). The Intravascular Cooling Adjunctive to Percutaneous Coronary Intervention for AMI (ICE-IT trial, n=228) presented similar result with the COOL-MI; no difference in overall, except for reduction of infarct size in anterior myocardial infarction subgroup.

Summary of published three RCTs, including one pilot study

Table 1. Summary of Clinical Studies Using Variable Strategies of Therapeutic Hypothermia

| Method of cooling                  | Rate of cooling  | Patient population         | Comments                                           |
|-----------------------------------|-----------------|---------------------------|---------------------------------------------------|
| Surface cooling                   | 0.9°C/hr        | ROSC after OHCA           | Slow cooling rate                                 |
| Topical trunk pad                 | 79 min to target <34.5°C (1.5°C/hr) | AMI           | Pilot study                                        |
| Convective-immersion              | 37 min to target <34°C (3°C/hr) | ROSC after OHCA           |                                                   |
| Transnasal evaporative cooling    | 1.3°C/26 min, before hospital arrival | Cardiac arrest | Performed by emergency responder                  |
| Intravenous infusion of cold saline (4°C) | 4.0±0.3°C/first 1 hr | Patients with neurologic injury | Rapid induction but problems related to cold fluid overloading |
| Endovascular cooling-catheter     | 3°C/hr in pilot study | AMI                       | Induce and maintain TH without infusion cold fluids to patients |
| Automated peritoneal lavage       | 8°C/hr          | Witnessed cardiac arrest  | Increased MACE                                    |

ROSC, return of spontaneous circulation; OHCA, out of hospital cardiac arrest; AMI, acute myocardial infarction; TH, therapeutic hypothermia; MACE, major adverse cardiac event within 30 days.

http://dx.doi.org/10.3349/ymj.2016.57.2.291
for cardioprotection of AMI, is presented in Table 2. The Rapid Cooling by Cold Saline and Endovascular Cooling Before Reperfusion in Patients with ST-Elevation Myocardial Infarction: Rapid MI-ICE\textsuperscript{[22]} (n=18) was a small number pilot study and showed reduction of infarct size/area at risk % (38%, \(p=0.04\)). Strength of this pilot study is no delay in TH group of door to balloon time and 100% achievement of hypothermia ≤35°C at the time of reperfusion. Additionally, HF at 45 days developed only in control group (n=3). There was no major bleeding in both groups, but TH group was related with 3 cases of infection.

A pooled analysis of ICE-IT and rapid MI-ICE trials, pre-Chill-MI, showed overall 37% relative reduction of infarct size in TH group who actually achieved core temperature ≤35°C at the time of reperfusion for both anterior (\(p=0.03\)) and inferior infarcts (\(p=0.04\)).\textsuperscript{[27]}

After pilot study, Chill-MI trial\textsuperscript{[24]} was performed using similar combined hypothermia method. However, in this multicenter RCT, total cooling maintenance time was shorter than the pilot study (1 hr vs. 3 hrs in rapid MI-ICE) and only 76% patients achieved core temperature ≤35°C at the time of reperfusion. Furthermore, TH group showed increased door to balloon time of 9 min. Their results failed to show overall reduction of infarct size, but revealed anterior wall infarct-related reduction of infarct size (33%, \(p=0.046\)) and decreased incidence of HF in 45 days (3% vs. 14% of control, \(p=0.047\)). These half successful results, compared to pilot study\textsuperscript{[22]} and pooled analysis,\textsuperscript{[3]} might have been due to shorter cooling maintenance time, lower achievement rate of hypothermia at the time of perfusion, and slightly delayed door to balloon time in TH group.

Another pool analysis\textsuperscript{[23]} from Rapid MI-ICE and Chill-MI demonstrated that TH is more effective in large myocardium at risk, anterior wall infarction and reduced post infarction-HF; however, patients with myocardium at risk <30% show no benefit.

The Evaluation of Ultrafast Hypothermia Before Reperfusion in STEMI Patients (VELOCITY) trial\textsuperscript{[23]} was performed by using automated peritoneal lavage device. Despite of rapid cooling rate of peritoneal cooling device, this RCT presented disappointed results; 1) delayed door to balloon time of median 15 minutes in TH group, 2) failed to show reduction of infarct size and microvascular obstruction, and 3) increased 30 days major adverse cardiac event (MACE) in TH group; stent thrombosis was evident only in TH group.

The association of TH with stent thrombosis was an important question in this RCT. It might be related to peritoneal cooling methods; delayed gastric absorption and reduced bioavailability of oral antiplatelet agents\textsuperscript{[25]} or direct effect.\textsuperscript{[26]} Although not certain, the delayed reperfusion in the hypothermia group might have attenuated the effect of hypothermia on infarct size. Furthermore, peritoneal cooling system may be related to several safety concerns; respiratory distress due to decreased diagram excursion coupled with use of sedation, major organ bleeding after peritoneal puncture, and limited candidate due to abdominal pathology or previous surgery.

Besides the VELOCITY trial, other RCTs and pooled analyses showed that combined hypothermia of intravenous cold saline infusion and endovascular cooling catheter was feasible and safe for cardioprotection in AMI. Similar to experimental studies, RCTs showed effectiveness of rapid and early achieved TH at the time of reperfusion to reduce infarct size and even slightly delayed TH was also effective for decrease of HF incidence. In addition, TH is more effective on large myocardium at risk and anterior wall infarction.

**CONSIDERATIONS FOR CLINICAL USES**

Most important issue is how to achieve target temperature rapidly without delaying door to balloon time: such as simple and easy method to start at emergency department or even before hospital. Most RCTs adopted methods combined intravenous cold saline infusion and endovascular cooling catheter, and small pilot study was successful but multicenter RCT. Experienced team approach may improve the cooling rate without increasing infection. In this method, hypothermia was induced by rapid infusion of 600–2000 mL of cold saline under physicians decision.\textsuperscript{[23–24]} Consequently, cooling rate depends on the volume of administration and may have variation according to the volume. However, a large volume infusion of cold saline is inadequate for some patients and has a chance

---

**Table 2. Summary of Randomized Clinical Trials of Therapeutic Hypothermia in Patients with Acute Myocardial Infarction**

| Clinical trials (yrs) number | Cooling method | Target °C (cooling rate) | Cooling duration & rewarming | Door to balloon time control vs. study (min) | Results (IS/Δ at risk) |
|-----------------------------|----------------|--------------------------|-------------------------------|-------------------------------------------|------------------------|
| Rapid MI-ICE\textsuperscript{[22]} (2010) n=18 | IV cold saline with endovascular catheter | 33°C (4.3–8.4°C/hr)* | Total 3 hrs, passive rewarming: 3 hrs | 43±7 vs. 40±6 | \(p=0.04\) (by 4 days MRI) HF; 0 vs. 3 |
| CHILL-MI\textsuperscript{[23]} (2014) n=120 | IV cold saline with endovascular catheter | 33°C (2.8–6°C/hr)* | Total 1 hr, passive rewarming: 3 hrs | 33±12 vs. 42±16 | \(p=0.15\) (by 4 days MRI) HF; \(p=0.047\) |
| VELOCITY\textsuperscript{[23]} (2015) n=54 | Automated peritoneal lavage system | \(≤34.9°C (9°C/hr)\) | 3 hrs after PCI, active rewarming: 0.5°C/hr | 47 (37.55) vs. 62 (51.81) | \(p=0.43\) (by 30 days MRI) Higher MACE |

IS/Δ at risk, infarct size/area at risk; IV, intravenous; MRI, magnetic resonance image; HF, 45 days heart failure; MACE, major adverse cardiac event within 30 days.

\(^*\)Means (total mean—mean catheter) cooling rate, \(^*\)Means median (interquartile range).

http://dx.doi.org/10.3349/ymj.2016.57.2.291
of pulmonary edema and worsened ejection fraction. A pad type topical surface cooling, transnasal evaporative cooling or other methods can be considered as a substitute of a large volume cold saline infusion in that case.

Rapid induction of TH in conscious AMI patients may cause physical and psychological discomfort, including fear, resist and shivering. Competent medical treatment is important; neuromuscular blocker for shivering and meperidine with or without oral buspirone.

Cooling should be maintained during the first one hour of reperfusion, even though cooling had been instituted early in the ischemic period, since TH during reperfusion prevents microvascular damage, obstruction and no-reflow phenomenon. However, there is a lack of information regarding how long cooling should be maintained after reperfusion to achieve maximal cardioprotective effect. According to the result of Chill-MI, one hour cooling may not be enough; although they continued cooling longer than one hour until the end of the procedure, if the PCI procedure takes longer than one hour. Topics regarding the effect of prolonged cooling need to be further investigated.

FUTURE DIRECTIONS

Concerning effectiveness of reducing infarct size, lower temperature gains better result. Mild TH, which ranges from 32 to 35°C, is generally well tolerated in mammalian and human. Hence, to obtain target temperature as low as 32°C is important to achieve maximum infarct size reduction in patients with AMI. 1) Invention of clinically applicable devices and medications, 2) optimization of protocols and medical support during cooling and rewarming periods, and 3) diversification of cooling devices and dealing with safety issues; e.g., local cooling device are important topics to achieve target 32°C.

CONCLUSIONS

Most RCTs and pooled analyses have been conducted with combined methods of intravenous cold saline infusion and endovascular cooling catheter. They showed feasibility and safety of TH for cardioprotection in AMI. Similar to experimental studies, the RCTs showed effectiveness of rapid and early achieved TH at the time of reperfusion to reduce infarct size, and that even slightly delayed TH is also effective to decrease incidence of post-infarction HF. In addition, TH is more effective in large myocardium at risk and anterior wall infarction.

Hence, rapid cooling without delaying reperfusion therapy is the most important for successful outcomes. Diversification of cooling devices and experienced team approach may improve the cooling rate without increasing complications and also achieve target temperature of 32°C. A topical surface cooling, transnasal evaporative cooling or other methods can be considered as an initial cooling induction combined with rapid cooling devices, e.g., endovascular catheter. Furthermore, more experimental studies for developing ideal strategies, including clinically applicable devices and medications, are needed. Finally, well conducted larger RCTs in AMI patients are needed.

REFERENCES

1. Thyesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581-98.
2. Minicucci MF, Azevedo PS, Polegato BF, Paiva SA, Zornoff LA. Heart failure after myocardial infarction: clinical implications and treatment. Clin Cardiol 2011;34:410-4.
3. Lee S, Baek K, Chun K. Cost-effectiveness of drug-eluting vs. bare-metal stents in patients with coronary artery disease from the Korean National Health Insurance Database. Yonsei Med J 2014;55:1533-41.
4. Oh PC, Choi IS, Ahn T, Moon J, Park Y, Seo JG, et al. Predictors of recovery of left ventricular systolic dysfunction after acute myocardial infarction: from the Korean acute myocardial infarction registry and Korean myocardial infarction registry. Korean Circ J 2013;43:527-33.
5. Lopez AD. Assessing the burden of mortality from cardiovascular diseases. World Health Stat Q 1993;46:91-6.
6. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:e44-e122.
7. Berger PB, Ellis SG, Holmes DR Jr, Granger CB, Criger DA, Betriu A, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIIb) trial. Circulation 1999;100:14-20.
8. Sim DS, Ahn Y, Kim YH, Seon HJ, Park KH, Yoon HJ, et al. The Relationship among N-Terminal Pro-B-Type Natriuretic Peptide, High-Sensitivity C-Reactive Protein and Infarct Size in Patients with Acute ST-Elevation Myocardial Infarction. Korean Circ J 2015;45:285-93.
9. Rathore SS, Curtis JP, Chen J, Wang Y, Nallamothu BK, Epstein AJ, et al. Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. BMJ 2009;338:b1807.
10. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357:1121-35.
11. Yoon HJ, Jeong MH, Jeong Y, Kim KH, Song JE, Cho JY, et al. Progressive dilation of the left atrium and ventricle after acute myocardial infarction is associated with high mortality. Korean Circ J 2013;43:731-8.
12. Inoue T. Ischemia-reperfusion injury is still a big hurdle to overcome for treatment of acute myocardial infarction. J Cardiol 2015 Dec 13 [Epub]. http://dx.doi.org/10.1016/j.jjcc.2015.09.002.
13. Kimura K, Nakao K, Shibata Y, Sone T, Takayama T, Fukuzawa S, et al. Randomized controlled trial of TY-51924, a novel hydrophilic NHE inhibitor, in acute myocardial infarction. J Cardiol 2015 Sep 7 [Epub]. http://dx.doi.org/10.1016/j.jjcc.2015.07.017.
14. Nolan JP, Morley PT, Vanden Hoek TL, Hickey RW, Kloek WG, Billi J, et al. Therapeutic hypothermia after cardiac arrest: an advisory statement by the advanced life support task force of the International Liaison Committee on Resuscitation. Circulation 2003;108:118-21.

15. Schwartz BG, Kloner RA, Thomas JL, Bui Q, Mayeda GS, Burstein S, et al. Therapeutic hypothermia for acute myocardial infarction and cardiac arrest. Am J Cardiol 2012;110:461-6.

16. Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002;346:549-56.

17. Duncker DJ, Klassen CL, Ishibashi Y, Herrlinger SH, Pavek TJ, Bache RJ. Effect of temperature on myocardial infarction in swine. Am J Physiol 1996;270(4 Pt 2):H1189-99.

18. Hale SL, Kloner RA. Ischemic preconditioning and myocardial hypothermia in rabbits with prolonged coronary artery occlusion. Am J Physiol 1999;276(6 Pt 2):H2029-34.

19. Tissier R, Couvreur N, Ghalab B, Bruneval P, Lidouen F, Morin D, et al. Rapid cooling preserves the ischaemic myocardium against mitochondrial damage and left ventricular dysfunction. Cardiovasc Res 2009;83:345-53.

20. Herring MJ, Hale SL, Dai W, Osukui PM, Kloner RA. Hypothermia in the setting of experimental acute myocardial infarction: a comprehensive review. Ther Hypothermia Temp Manag 2014;4:159-67.

21. Hale SL, Dae MW, Kloner RA. Hypothermia during reperfusion limits ‘no-reflow’ injury in a rabbit model of acute myocardial infarction. Cardiovasc Res 2003;59:715-22.

22. Göteborg M, Olivecrona GK, Koul S, Carlsson M, Engholm H, Ugander M, et al. A pilot study of rapid cooling by cold saline and endovascular cooling before reperfusion in patients with ST-elevation myocardial infarction. Circ Cardiovasc Interv 2010;3:400-7.

23. Erlinge D, Göteborg M, Lang I, Holzer M, Noc M, Clemenenson P, et al. Rapid endovascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. The CHILL-MI trial: a randomized controlled study of the use of central venous catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. J Am Coll Cardiol 2014;63:1857-65.

24. Erlinge D, Göteborg M, Noc M, Lang I, Holzer M, Clemenenson P, et al. Therapeutic hypothermia for the treatment of acute myocardial infarction–combined analysis of the RAPID MI-ICE and the CHILL-MI trials. Ther Hypothermia Temp Manag 2015;5:77-84.

25. Nichol G, Strickland W, Shaville D, Ben-Yehuda O, Genereux P, et al. Prospective, multicenter, randomized, controlled pilot trial of peritoneal hypothermia in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2015;8:e001965.

26. Kim CY, Bae MH, Kim NK, Yang YA, Kim KY, Lee JH, et al. Case of recurrent ventricular fibrillations with osborn wave developed during therapeutic hypothermia. Korean J Clin 2015;45:81-4.

27. Tissier R, Chenoune M, Ghalab B, Cohen MV, Downey JM, Berdeaux A. The small chill: mild hypothermia for cardioprotection? Cardiovasc Res 2010;88:406-14.

28. Hamamoto H, Sakamoto H, Leshnower BG, Parish LM, Kanemoto S, Hamamoto H, et al. Very mild hypothermia during ischemia and reperfusion improves postinfarction ventricular remodeling. Ann Thorac Surg 2009;87:172-7.

29. McAllindon E, Bucciarelli-Ducci C, Suleiman MS, Baumbach A. Infarct size reduction in acute myocardial infarction. Heart 2015;101:155-60.

30. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wave-front phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977;56:786-94.

31. Tekin K, Cagliyan CE, Tanboga IH, Balli M, Uysal OK, Ozkan B, et al. Influence of the timing of percutaneous coronary intervention on clinical outcomes in non-ST-elevation myocardial infarction. Korean Circ J 2013;43:725-30.

32. Kim KH, Kim W, Kang WY, Hwang SH, Cho SC, Kim W, et al. The impact of ischemic time on the predictive value of high-sensitivity C-reactive protein in ST-segment elevation myocardial infarction patients treated by primary percutaneous coronary intervention. Korean Circ J 2013;43:664-73.

33. Masoudi FA, Bonow RO, Brindis RG, Cannon CP, Debuhr J, Fitzgerald S, et al. ACC/AHA 2008 statement on Performance Measurement and Reperfusion Therapy: a report of the ACC/AHA Task Force on Performance Measures (Work Group to address the challenges of Performance Measurement and Reperfusion Therapy). J Am Coll Cardiol 2008;52:2100-12.

34. Fröhlich GM, Meier P, White SK, Yellow DM, Hausenloy DJ. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J 2013;34:1714-22.

35. Chun WJ, Nah DY, Bae JH, Chung JW, Lee H, Moon IS. Glucose-insulin-potassium solution protects ventricular myocytes of neonatal rat in an in vitro coverslip ischemia/reperfusion model. Korean J Cir 2015;45:234-41.

36. Kim NH, Kang PM. Apoptosis in cardiovascular diseases: mechanisms and clinical implications. Korean Circ J 2010;40:299-305.

37. Nah DY, Rhee MY. The inflammatory response and cardiac repair after myocardial infarction. Korean J Cir 2009;39:393-8.

38. Polderman KH, Noc M, Kurz M, Alibki M. Therapeutic hypothermia in post-cardiac arrest and myocardial infarction. Ther Hypothermia Temp Manag 2015;5:193-7.

39. Simkhovich BZ, Hale SL, Kloner RA. Metabolic mechanism by which mild regional hypothermia preserves ischemic tissue. J Cardiovasc Pharmacol Ther 2004;9:83-90.

40. Yang X, Liu Y, Yang XM, Hu F, Cui L, Swingle MR, et al. Cardioprotection by mild hypothermia during ischemia involves preservation of ERK activity. Basic Res Cardiol 2011;106:421-30.

41. Solenkova NV, Solodushko V, Cohen MV, Downey JM. Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. Am J Physiol Heart Circ Physiol 2006;290:H1441-9.

42. Hale SL, Kloner RA. Mild hypothermia as a cardioprotective approach for acute myocardial infarction: laboratory to clinical application. J Cardiovasc Pharmacol Ther 2011;16:131-9.

43. Kanemoto S, Matsubara M, Noma M, Leshnower BG, Parish LM, Jackson BM, et al. Mild hypothermia to limit myocardial ischemia-reperfusion injury: importance of timing. Ann Thorac Surg 2009;87:157-63.

44. Göteborg M, Olivecrona GK, Engholm H, Ugander M, van der Pals Götberg M, et al. Influence of the timing of percutaneous coronary intervention on treatment outcomes in patients with ST-segment elevation myocardial infarction. Yonsei Med J 2015;57:291-9.

45. http://dx.doi.org/10.3349/ymj.2016.57.2.291
56:1235-43.
48. Cheng R, Wei G, Yu L, Su Z, Wei L, Bai X, et al. Coronary flow reserve in the remote myocardium predicts left ventricular remodeling following acute myocardial infarction. Yonsei Med J 2014;55:904-11.
49. Howes D, Ohley W, Dorian P, Klock C, Freedman R, Schock R, et al. Rapid induction of therapeutic hypothermia using convective-immersion surface cooling: safety, efficacy and outcomes. Resuscitation 2010;81:388-92.
50. Ly HQ, Denault A, Dupuis J, Vadeboncoeur A, Harel F, Arsenault A, et al. A pilot study: the Noninvasive Surface Cooling Thermo-regulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (the NICAMI Study). Am Heart J 2005;150:933.
51. Castrén M, Nordberg P, Svensson L, Taccone F, Vincent JL, Desruelles D, et al. Intra-arrest transnasal evaporative cooling: a randomized, prehospital, multicenter study (PRINCE: Pre-ROSC Intranasal Cooling Effectiveness). Circulation 2010;122:729-36.
52. Polderman KH, Rijnsburger ER, Peerdeman SM, Girbes AR. Induction of hypothermia in patients with various types of neurologic injury with use of large volumes of ice-cold intravenous fluid. Crit Care Med 2005;33:2744-51.
53. Kandzari DE, Chu A, Brodie BR, Stuckey TA, Hermiller JB, Vetrovec GW, et al. Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOW-TEMP pilot study). Am J Cardiol 2004;93:636-9.
54. Wolff B, Machill K, Schumacher D, Schulzki I, Werner D. Early achievement of mild therapeutic hypothermia and the neurologic outcome after cardiac arrest. Int J Cardiol 2009;133:223-8.
55. O’Neill WW, Dixon SR. The year in interventional cardiology. J Am Coll Cardiol 2004;43:875-90.
56. O’Neill WW, Dixon SR, Grines CL. The year in interventional cardiology. J Am Coll Cardiol 2005;45:1117-34.
57. Erlinge D, Göteborg M, Grines C, Dixon S, Baran K, Kandzari D, et al. A pooled analysis of the effect of endovascular cooling on infarct size in patients with ST-elevation myocardial infarction. EuroIntervention 2013;8:1435-40.
58. Straub A, Krajewski S, Holmman JD, Westein E, Jia F, Bassler N, et al. Evidence of platelet activation at medically used hypothermia and mechanic data indicating ADP as a key mediator and therapeutic target. Arterioscler Thromb Vasc Biol 2011;31:1607-16.